Mutations in Genes Related to Temozolomide Resistance in High-Grade Gliomas
Author Information
Author(s): Darío Ortiz Gómez León, Heidy Johanna Contreras Martínez, David Andrés Galvis Pareja, Sara Vélez Gómez, Jorge Emilio Salazar Flórez, Fernando P. Monroy, Ronald Guillermo Peláez Sánchez
Primary Institution: CES University and Americas-AUNA Clinic
Hypothesis
The study aims to identify genetic mutations associated with resistance to temozolomide in patients with high-grade gliomas.
Conclusion
Mutations in the PIK3C2B, ERBB3, KIT, and MLH1 genes may be related to the response to temozolomide treatment in patients with high-grade gliomas.
Supporting Evidence
- Mutations in PIK3C2B, ERBB3, KIT, and MLH1 were significantly associated with a second relapse in patients treated with temozolomide.
- Patients with mutations in these genes had a shorter progression-free survival compared to those without mutations.
- Statistical analysis showed that PIK3C2B had a hazard ratio of 82.37, indicating a strong association with treatment resistance.
Takeaway
Some patients with brain tumors don't get better with a common treatment called temozolomide because of changes in certain genes. Finding these changes can help doctors understand who might need different treatments.
Methodology
The study involved sequencing 324 cancer-related genes in 31 patients diagnosed with high-grade gliomas to identify mutations related to temozolomide resistance.
Limitations
The small sample size of 31 patients limits the statistical power and generalizability of the findings.
Participant Demographics
The mean age of participants was 47 years, with 11 males (35.49%) and 20 females (64.51%).
Statistical Information
P-Value
p=0.004 for PIK3C2B
Confidence Interval
95% CI: 2.25–84.45 for PIK3C2B
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website